ReviewViruses2012
Animal models, prophylaxis, and therapeutics for arenavirus infections.
Review in Viruses, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Lassa Virus-A Persistent and Evolving Threat.Microorganisms · 2026Review
- Development and protective evaluation of mRNA vaccines encoding the glycoprotein precursor of lymphocytic choriomeningitis virus.Virus research · 2026Article
- Coagulation Hemostasis Parameters in Macaque Monkeys (Macaca spp.).Bulletin of experimental biology and medicine · 2025Article
- Treatment of highly virulent mammarenavirus infections-status quo and future directions.Expert opinion on drug discovery · 2024Review
- Temporal changes in pathology and viral RNA distribution in guinea pigs following separate infection with two New World Arenaviruses.PLoS neglected tropical diseases · 2023Article
- Review
- Screening of Botanical Drugs against Lassa Virus Entry.Journal of virology · 2021Article
- Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library.Frontiers in microbiology · 2021Article
- Article
- Hematology and Clinical Chemistry Reference Intervals for Inbred Strain 13/n Guinea Pigs (Journal of the American Association for Laboratory Animal Science : JAALAS · 2019Article
- Prevalence of Wēnzhōu virus in small mammals in Yunnan Province, China.PLoS neglected tropical diseases · 2019Article
- Article
- Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells.PLoS pathogens · 2018Article
- Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.Journal of virology · 2018Article
- Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever.PLoS pathogens · 2016Article
- Human hemorrhagic Fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis.Pathogens (Basel, Switzerland) · 2015Review
- Infectious disease. Combating emerging viral threats.Science (New York, N.Y.) · 2015Article
- A host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress.Journal of virology · 2014Article
- Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections.The Journal of general virology · 2014Review
- Innate immune response to arenaviral infection: a focus on the highly pathogenic New World hemorrhagic arenaviruses.Journal of molecular biology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arenaviruses are enveloped, bipartite negative single-stranded RNA viruses that can cause a wide spectrum of disease in humans and experimental animals including hemorrhagic fever. The majority of these viruses are rodent-borne and the arenavirus family can be divided into two groups: the Lassa-Lymphocytic choriomeningitis serocomplex and the Tacaribe serocomplex. Arenavirus-induced disease may include characteristic symptoms ranging from fever, malaise, body aches, petechiae, dehydration, hemorrhage, organ failure, shock, and in severe cases death. Currently, there are few prophylactic and therapeutic treatments available for arenavirus-induced symptoms. Supportive care and ribavirin remain the predominant strategies for treating most of the arenavirus-induced diseases. Therefore, efficacy testing of novel therapeutic and prophylactic strategies in relevant animal models is necessary. Because of the potential for person-to-person spread, the ability to cause lethal or debilitating disease in humans, limited treatment options, and potential as a bio-weapon, the development of prophylactics and therapeutics is essential. This article reviews the current arenavirus animal models and prophylactic and therapeutic strategies under development to treat arenavirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.